Methotrexate Increases Serum Calcium Levels in Patients with Rheumatoid Arthritis: A Retrospective Study at a Referral Hospital in Indonesia Authors: Dika P. Destiani, Vida M. Utami, Syifa Farhanah, Sofa D. Alfian, Sumartini Dewi, Syed A.S. Sulaiman, Rizky Abdulah Published: 2023 ABSTRACT BackgroundRheumatoid arthritis (RA) is a significant issue, particularly in bone health problems, because it can prolong diseases like secondary osteoporosis. Subsequently, the anchor of drug therapy for RA is methotrexate (MTX), which also has the potential to reduce the risk of secondary osteoporosis.ObjectiveThis study aims to examine the effect of MTX on calcium levels, an important parameter for monitoring bone health and the risk of secondary osteoporosis in patients with RA.MethodsA retrospective study was carried out by collecting data from the medical records of patients, which included demographic and patient characteristics, treatment data (drug and dosage), duration of treatment, and calcium levels. All patients were diagnosed with RA and fell within the age range of 18 to 59 years. Additionally, the effectiveness of MTX therapy was compared with other treatments, categorizing patient data accordingly. Statistical analyses, such as χ2 and ordinal regression, using IBM-SPSS Statistics version 25 (IBM-SPSS Inc, Armonk, New York) were used to establish associations between MTX treatment and calcium levels, reporting odds ratio and 95% CI values.ResultsThe data consisted of 123 patients with RA, comprising 99 who had a history of MTX use for more than 6 months and 24 who either did not use MTX or used it for <6 months. The majority of patients were women and their ages ranged between 40 and 59 years. MTX monotherapy was the most used with a dose range of 7.5 to 15 mg. Furthermore, this study observed that patients treated with MTX between 7.5 and 15 mg have lower serum calcium levels than those who received 17.5 to 25 mg (P = 0.022; odds ratio = 5.663; 95% CI, 0.251–3.218). Most patients with RA using MTX maintained normal calcium levels. No significant differences were observed between single MTX therapy and combination therapy.ConclusionsAlthough further investigation is needed, this study showed the potential properties of MTX in maintaining patients’ serum calcium levels, which may help to reduce the risk of secondary osteoporosis in patients with RA. Introduction Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammation in the synovium of joints,1 particularly affecting smaller parts of the hands and feet. Several inflammatory cytokines are included in RA such as tumor necrosis factor-α, interleukin-1, interleukin-6, and interleukin-17. These cytokines activate osteoclasts, which causes bone erosion.2 Chronic inflammation in RA increases the receptor activator of nuclear factor kappa-B ligand (RANKL) expression and decreases osteoprotegerin, leading to secondary osteoporosis.3 Regular monitoring of secondary osteoporosis is essential through bone mineral examinations.4 The primary goal of RA therapy is to prevent the progression of bone erosion.5 The results of previous systematic review studies showed that methotrexate (MTX) has a good effect on bone erosion.6 Although the exact mechanism through which MTX prevents bone erosion remains unclear, several studies have shown its ability to inhibit the progression of bone erosion.7,8 There are several methods used to monitor bone health, including the use of radiography, magnetic resonance imaging, X-ray, bone mineral density (BMD) examination, or other bone minerals values.6,9,10 Subsequently, it is important to note that some hospitals or health services in developing countries may experience limitations in carrying out these examinations because not all are covered by health insurance. However, there are alternative, cost-effective options for patients in developing countries to assess their bone health. One readily accessible parameter is calcium level, which plays a crucial role in maintaining bone health.11 Several studies have established a relationship between total serum calcium level and ionized calcium with BMD, making it a useful parameter for assessing bone erosion. High serum calcium levels indicate a decrease in BMD (T score).12,13 In patients with RA, calcium absorption is usually impaired.14 Several factors in patients with RA can interfere with calcium absorption. The use of glucocorticoids in RA can also inhibit calcium absorption in the intestine and accelerate its excretion in the renal system.3 Previous studies have shown that impaired calcium metabolism influences the decrease in blood calcium levels.15 Studies on the effect of MTX in reducing secondary osteoporosis in patients with RA through serum calcium levels assessment remain limited. Aim This study aims to investigate the effect of MTX on calcium levels in patients with RA to examine its potential role in reducing the risk of secondary osteoporosis. Ethics approval The study was conducted following the Helsinki Declaration guidelines with ethical approval obtained from the Research Ethics Committee of Universitas Padjadjaran (423/UN6.KEP/EC/2020). Informed consent was obtained from all participants. Patient files were processed anonymously, and no personal data were collected. Methods This retrospective study collected data from the medical records of patients and was conducted in a referral hospital in West Java Province, the most populous province in Indonesia, covering 48,220,094 million people.16 Medical records of adult outpatients (aged 18 to 59 years) diagnosed with RA who came to the rheumatology clinic from 2011 to 2021 were collected from December 2021 to January 2022, including demographic and patients characteristics such as gender and age, comorbidities or other diseases, treatment data (drug and dose), duration of treatment, and serum calcium levels. All patients received at least 6 months of RA therapy, and the use of glucocorticoids as bridging therapy (6 months with low and moderate doses with <7.5 mg/7.5–30 mg prednisone equivalent) was included because this regimen was consistent with the guideline therapy in Indonesia.17,18 Furthermore, patients prescribed bisphosphonates, barbiturates, anticonvulsant agents, vitamin D, and thyroid hormone medications were excluded because of their effect on the incidence of osteoporosis and bone mineral values. The χ2 test and multivariate ordinal regression were used to analyze the association between MTX treatment and serum calcium levels using IBM-SPSS Statistics version 25 (IBM-SPSS Inc, Armonk, New York). This study adhered to Strengthening the Reporting of Observational Studies in Epidemiology guidelines for cross-sectional studies (see the Supplemental Table and the Supplemental Data in the online version at doi:10.1016/j.curtheres.2023.100726).19 Results In this study, out of the 140 patients diagnosed with RA, 123 met the inclusion criteria. Among these 123 patients, 99 had a history of using MTX for at least 6 months, whereas the other 24 used other drugs (non-MTX) or used MTX for <6 months. Serum calcium levels were analyzed in all 123 patients to assess disease progression and the risk of developing secondary osteoporosis, with 1 of the assessments focusing on serum calcium levels. A normal serum calcium level is 8.6 to 10 mg/dL.20 The results of the test are presented in Table 1.Table 1Calcium serum levels of patients with rheumatoid arthritis (RA).Table 1Calcium level, mg/dLTotal patients with RA (n = 123)RA patients used at least 6 mo of MTXGroup 1Group 2Group 3Group 4Group 1Group 2Group 3MTX monotherapyMTX combinationStopped MTXNon-MTXMTX monotherapyMTX combinationStopped MTX>1041002108.6–10*5420176442015<8.6144121241MTX = methotrexate.⁎Normal. Table 1Calcium serum levels of patients with rheumatoid arthritis (RA).Table 1Calcium level, mg/dLTotal patients with RA (n = 123)RA patients used at least 6 mo of MTXGroup 1Group 2Group 3Group 4Group 1Group 2Group 3MTX monotherapyMTX combinationStopped MTXNon-MTXMTX monotherapyMTX combinationStopped MTX>1041002108.6–10*5420176442015<8.6144121241MTX = methotrexate.⁎Normal. Calcium serum levels of patients with rheumatoid arthritis (RA). MTX = methotrexate. Normal. The total groups of patients were compared for their serum calcium levels using statistical analysis. Additionally, other variables, such as the association between the dose and duration of MTX therapy on serum calcium levels, were also subjected to statistical analysis. The results of these analyses are presented in Table 2.Table 2Association between methotrexate (MTX) with calcium serum levels.*Table 2CharacteristicnEstimateP valueOdds ratio95% CILower boundUpper boundTherapy received (n = 123) MTX monotherapy72–0.5730.5280.564–2.3551.209 Combination therapy25–0.8610.3830.423–2.7951.074 Stopped MTX18–1.1840.2660.306–3.2700.902 Non-MTX8–––––MTX dose (n = 99) 7.5–15631.7340.0225.6630.2513.218 17.5–2536–––––Duration of therapy, mo (n = 99) 6–1218-1.8450.3560.158-5.7612.071 13–24171.3660.0683.920-0.0992.832 >2450–––––⁎Odds ratios were adjusted for gender, age, comorbidities, and duration of rheumatoid arthritis. Table 2Association between methotrexate (MTX) with calcium serum levels.*Table 2CharacteristicnEstimateP valueOdds ratio95% CILower boundUpper boundTherapy received (n = 123) MTX monotherapy72–0.5730.5280.564–2.3551.209 Combination therapy25–0.8610.3830.423–2.7951.074 Stopped MTX18–1.1840.2660.306–3.2700.902 Non-MTX8–––––MTX dose (n = 99) 7.5–15631.7340.0225.6630.2513.218 17.5–2536–––––Duration of therapy, mo (n = 99) 6–1218-1.8450.3560.158-5.7612.071 13–24171.3660.0683.920-0.0992.832 >2450–––––⁎Odds ratios were adjusted for gender, age, comorbidities, and duration of rheumatoid arthritis. Association between methotrexate (MTX) with calcium serum levels.* Odds ratios were adjusted for gender, age, comorbidities, and duration of rheumatoid arthritis. This study investigated the association between using >6 months MTX therapy (in single therapy of MTX, MTX combination with other disease-modifying antirheumatic drugs (DMARDs), changing MTX to other DMARDs or biological DMARDs, and <6 months or non-MTX therapy with serum calcium levels. The results revealed that no significant differences were observed. Another result found that patients treated with 7.5 to 15 mg MTX had lower serum calcium levels than those who received 17.5 to 25 mg (odds ratio = 5.663; 95% CI, 0.251–3.218; P = 0.022). However, the duration of MTX treatment did not yield significant results. Discussion Statement of key results Most patients with RA are treated using MTX monotherapy. This study indicates that there are no significant differences in serum calcium levels between MTX monotherapy and combination therapy. Serum calcium levels may be used to indicate the signs of secondary osteoporosis. Chronic RA could elevate RANKL expression, leading to increased bone resorption and subsequent osteoporosis development.21 Increased bone resorption may cause hypercalcemia, and 1 study also found that hypercalcemia could be linked to lower BMD.22,23 Interpretation In this study, several variables that can influence the association between MTX therapy and serum calcium levels were considered. The odds ratio was obtained by adjusting sex, age, comorbidities, and duration of RA. This study found no difference between MTX single treatment, MTX combination, and other DMARDs treatments (without MTX). This means that MTX treatment had the same effect on serum calcium levels as other DMRADs. Subsequently, MTX is called the RA anchor of drug therapy with good effectiveness and minimal side effects.24,25 This study also found that patients receiving MTX therapy with weekly doses in the range of 7.5 to 15 mg exhibited lower serum calcium levels than those receiving higher doses (odds ratio = 5.663; P = 0.022). In the context of RA treatment, patients typically receive gradually tapered MTX doses, with adjustments made every 2 to 4 weeks until achieving the therapeutic goal.26 Inflammation that occurs in patients with RA increases the production and activity of proinflammatory cytokines, which cause bone loss and brittleness through increasing RANKL expression. When RANKL expression increases, it activates osteoclasts and promotes bone loss through processes such as resorption imbalance.27 MTX has the potential to reduce inflammation and have positive effects on bone. However, data regarding its effectiveness in preventing bone fragility is still limited. Low-dose MTX as in RA therapy has not shown detrimental effects on BMD.27, 28, 29 The effect of MTX depends on the dose administered, where high doses of MTX can lead to osteopathy, whereas low doses have the potential to reduce the risk of bone erosion.30 Patients with higher RANKL-induced calcium influx may benefit from higher MTX doses, resulting in higher serum calcium levels. Indirectly, MTX inhibits osteoclastogenesis by reducing RANKL-induced calcium influx into osteoclast progenitors.31 Therefore, bone resorption can decrease and subsequently lead to normal serum calcium levels. Strengths and weakness According to the data, patients who received MTX had normal calcium levels, and MTX can also reduce secondary osteoporosis by decreasing bone erosion. However, it is important to note that this study has certain limitations, and among the significant limitations is the potential for bias due to indication. There were several restrictions on the examination due to the situation and conditions in the field. In addition, this study is retrospective and the data were obtained from secondary data (medical records) except for serum calcium levels. These medical records might not have been consistently organized, leading to incomplete treatment histories and examination records. Further study Further prospective studies will be required to examine other bone health indicators, including BMD and radiography. The examination of other markers of bone resorption, such as osteoprotegerin, RANKL, Dkk-1, and sclerostin, can also be a study object in future studies. Conclusions Despite the limitations, this study showed the potential roles of MTX in increasing serum calcium levels of patients with RA. Therefore, it is tempting to speculate about its further role in preventing secondary osteoporosis in patients with RA. Declaration of Competing Interest The authors have indicated that they have no conflicts of interest regarding the content of this article.